Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.
Stocks · News reference
Dentsply Sirona Q2 Adj. EPS $0.52 Beats $0.35 Estimate, Sales $898.000M Beat $889.810M Estimate
Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.35 by 48.57 percent. This is unchanged from the same period last year. The company reported
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dentsply Sirona's Wellspect HealthCare Announces U.S. Launch Of Surity Urinary Management System, Completing Surity External Catheter Portfolio
8-K/A filing — DENTSPLY SIRONA Inc. (XRAY)
Filed: 2026-08-07 AccNo: 0000818479-26-000263 Size: 615 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est
Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500 billion-$3.600 billion